Today, October 12th, the Janssen Pharmaceutical Companies of Johnson & Johnson stand with the European League Against Rheumatism in support of World Arthritis Day, an annual event to raise awareness of rheumatic and musculoskeletal diseases.
At Janssen, we understand the impact that conditions like rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis have each and every day on patients and their loved ones. For the past twenty years, we have made it our mission to address these challenges through the development of advanced biologic therapies. While these important medicines have changed the way these diseases are treated, we still strive to do for more patients.
Today, our scientists are advancing the latest research to discover and develop the next generation of medicines that will provide new, more personalized approaches in addressing individual patient needs. We look to the future, motivated by the successes we have seen over the years, and inspired by the challenges we recognize still exist for many people living with the pain, inflammation and limitations associated with rheumatic diseases.
As we look to the future, we envision #aworldfreefrom immune and inflammatory diseases like RA. That’s our vision and, today, on World Arthritis Day, our global Janssen team is taking action in advancing science to help those living with rheumatic and musculoskeletal diseases today and in the future.
Dan Baker, M.D., Vice President, R&D Disease Area Leader, Rheumatoid Arthritis, Janssen Pharmaceutical Companies of Johnson & Johnson.
Irene Hsu, PharmD, MBA, Vice President, Commercial Disease Area Leader, Rheumatoid Arthritis and Psoriasis, Janssen Pharmaceutical Companies of Johnson & Johnson.